临床试验/NCT03970733

NCT03970733已完成2 期

ALTERNATIVE SCHEDULE STUDY FOR VLA15, A MULTIVALENT RECOMBINANT OSPA BASED VACCINE CANDIDATE AGAINST LYME BORRELIOSIS, IN HEALTHY ADULTS AGED 18 TO 65 YEARS - A RANDOMIZED, CONTROLLED, OBSERVER-BLIND PHASE 2 STUDY.

Pfizer5 个研究点分布在 1 个国家目标入组 246 人开始时间: 2019年7月1日最近更新: 2023年4月21日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Pfizer
入组人数: 246
试验地点: 5
主要终点: GMTs for IgG Against Each OspA Serotype

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180.

In the Booster Phase subjects from the higher dose group who completed their primary immunization schedule according to protocol will be randomized 2:1 to receive an additional higher dose VLA15 vaccination or Placebo at Month 18.

Study duration in the Main Study Phase per subject is a maximum of 20 months. Overall study Duration is estimated to be 22 months.

Study duration per subject in the Booster Phase is a maximum of approximately 13 months.

Study duration per subject in the Main Study Phase and Booster Phase together is estimated to be a maximum of approximately 33 months.

Overall study duration (i.e., First-Subject-In to Last-Subject Out/ end of Booster Phase) is estimated to be approximately 37 months.

详细描述

This is a randomized, observer-blind (subject, Sponsor and investigator/site staff involved in Clinical Evaluation of subjects are blinded), Placebo controlled, multicenter Phase 2 study.

In Main Study Phase a total of 246 healthy subjects,aged 18 to 65 years, were randomized 2:2:1 to receive either VLA15 with Alum (lower or higher doser Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1 (Month 0), Day 57 (Month 2) and Day 180 (Month 6).

Subjects from the higher dose group who completed their primary immunization schedule according to protocol, will be randomized 2:1 to receive an additional injection of the higher dose VLA15 with Alum or Placebo in a Booster Phase. The additional vaccination is administered as intramuscular injection approximately 18 months after the first immunization.

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Prevention
盲法: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围: 18 Years 至 65 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 是

入选标准

•Main Study Phase:
•Subject is aged 18 to 65 years at the day of screening
•Subject is of good general health, including subjects with pharmacologically controlled chronic conditions;
•Subject has an understanding of the study and its procedures, agrees to its provisions,and gives written informed consent prior to any study-related procedures;
•If subject is of childbearing potential:
•Subject has a negative serum pregnancy test at screening;
•Subject agrees to employ adequate birth control measures for the duration of the study.
•Inclusion Criteria - Booster Phase:
•Randomization into higher dose group in the Main Study Phase
•No relevant protocol deviation in the Main Study Phase, i.e., included in the Per-Protocol population for the Day 208 interim analysis of the Main Study;
•Subject is of good general health, including subjects with pharmacologically controlled chronic conditions;
•Subject has an understanding of the study and its procedures, agrees to its provisions, and gives written informed consent prior to any study-related procedures;
•If subject is of childbearing potential:
•Subject has a negative Urine pregnancy test before booster vaccination;
•Subject agrees to employ adequate birth control measures for the duration of the study

排除标准

•Main Study Phase:
•Subject has a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB as suspected or diagnosed by a physician, or received treatment for LB within the last 3 months prior to screening;
•Subject received previous vaccination against LB.;
•Subject had a tick bite within 4 weeks prior to vaccination visit;
•Subject has a medical history of or currently has a clinically relevant disease (e.g. cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment. Subjects with pharmacologically controlled conditions like osteoarthritis, depression, or asthma are eligible;
•Subject has a medical history of or currently has a neuroinflammatory or autoimmune disease, including Guillain Barré Syndrome;
•Subject has a known thrombocytopenia, bleeding disorder, or received anticoagulants in the three weeks prior to each study vaccination, contraindicating I.M. vaccination as judged by the investigator;
•Subject has received an active or passive immunization within 28 days before or after any vaccination; except for influenza (seasonal or pandemic) vaccines which may be administered outside a 7-days interval before or after any trial vaccination;
•Subject has received any other non-registered medicinal product in another clinical Trial within 28 days prior to VLA15 vaccination and throughout the entire study period or has received a registered medicinal product in another clinical Trial within 28 days prior to VLA15 vaccination and up to Day 208;
•Subject has a known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired immunodeficiency, including infection with human immunodeficiency virus (HIV), Status post organ transplantation or immuno-suppressive therapy within 30 days prior to first vaccination. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent >=0.05 mg/kg/day. Topical and inhaled steroids are allowed;
•Subject has a history of anaphylaxis or severe allergic reactions or a known hypersensitivity or allergic reactions to one of the components of the vaccine; Subject had any malignancy in the past 5 years. If treatment for cancer was successfully completed more than 5 years ago and the malignancy is considered to be cured, the subject may be enrolled;
•Subject had acute febrile infections within 10 days prior to first vaccination;
•Subject is pregnant (positive serum pregnancy test at screening), has plans to become pregnant during the course of the study or is lactating at the time of enrollment. Women of childbearing potential that are unwilling or unable to employ an adequate birth Control measure for the duration of the study.
•Subject has donated blood or blood-derived products (e.g. plasma) within 30 days or received blood or blood-derived products (e.g. plasma) within 90 days prior to first vaccination in this study or plans to donate or use blood or blood products during the course of the study;
•Subject has any condition that, in the opinion of the investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would Limit the subject's ability to complete the study;
•Subject is committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
•Subject is in a dependent relationship with the sponsor, an investigator or other study team member, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, siblings, parents) as well as employees of the investigator or study center personnel.
•Exclusion Criteria - Booster Phase:
•Subject met an individual stopping criterion during the Main Study Phase;
•Subject has developed a chronic illness related to Lyme borreliosis (LB), an active symptomatic LB as suspected or diagnosed by a physician, or received treatment for LB within the last 3 months prior to vaccination visit;
•Subject has developed a clinically relevant disease (e.g. cardiovascular, respiratory, neurologic, psychiatric conditions) which poses a risk for further participation in the study, based on investigators judgement, such as individuals with poorly controlled or unstable disease, ongoing suspected or active inflammation, or poor compliance with pharmacologic treatment;
•Subject has developed a neuroinflammatory or autoimmune disease, including Guillain Barré Syndrome;
•Subject has developed an immunodeficiency, including known infection with human immunodeficiency virus (HIV), status post organ transplantation, or immuno-suppressive therapy within 30 days prior to vaccination visit. Immuno-suppressive therapy is defined as administration of chronic (longer than 14 days) prednisone or equivalent >= 0.05 mg/kg/day. Topical and inhaled steroids are allowed;
•Subject has developed anaphylaxis or severe allergic reactions;
•Subject has developed allergic reactions to one of the components of the vaccine;
•Subject has developed a malignancy;
•Subject has developed thrombocytopenia or received anticoagulants in the 3 weeks prior to the booster vaccination contraindicating I.M. vaccination as judged by the investigator;
•Subject has received any other non-registered medicinal product in another clinical trial within 28 days prior to VLA15 booster vaccination at Month 18 or plans to participate in another clinical trial with a non-registered medicinal product until Month 24;
•Subject is pregnant, or plans to become pregnant prior to Month 24, or is lactating. Women of childbearing potential that are unwilling or unable to employ an adequate birth control measure for the duration of the study;
•Subject has developed any condition that, in the opinion of the investigator, may compromise the subject's well-being, might interfere with evaluation of study endpoints, or would limit the subject's ability to complete the study;
•Subject has been committed to an institution (by virtue of an order issued either by the judicial or the administrative authorities);
•Subject is in a dependent relationship with the sponsor, an investigator or other study team member, or the study center. Dependent relationships include close relatives and household members (i.e. children, partner/spouse, sibling).

研究组 & 干预措施

Placebo

Placebo Comparator

Main Study Phase: placebo - Booster Phase: arm discontinued

干预措施: Placebo (Biological)

VLA15 with Alum higher dose

Experimental

Main Study Phase: VLA15 with Alum higher dose - Booster Phase: VLA15 higher dose or placebo

干预措施: VLA15 (Biological)

VLA15 with Alum lower dose

Experimental

Main Study Phase: VLA15 with Alum lower dose - Booster Phase: arm discontinued

干预措施: VLA15 (Biological)

结局指标

主要结局

GMTs for IgG Against Each OspA Serotype

时间窗: Day 208 (Month 7)

Geometric Mean Titers (GMTs) for Immunoglobulin G (IgG) against each Outer Surface Protein A (OspA) serotype ST1 to ST6, determined by Enzyme-Linked Immunosorbent Assay (ELISA) at Day 208 (Month 7)

次要结局

GMFR as Compared to Baseline for IgG Against Each OspA Serotype During the Main Study Phase(Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
Percentage of Participants With Related Unsolicited AEs During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
SCRs for Each OspA Serotype Specific IgG (ST1 to ST6): Booster PP Population(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
GMFR as Compared to Month 18 (Pre-booster) for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population(Month 18 (from where comparison was done), Month 19, Month 24 and Month 30)
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years(Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
Percentage of Participants With Related AESIs During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
Percentage of Participants With Unsolicited AEs During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
GMFRs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years(Day 1 (baseline), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
Percentage of Participants With Serious Adverse Events (SAEs) During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
GMFR as Compared to Baseline for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population(Day 1 (baseline from where comparison was done), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
Percentage of Participants With Related SAEs During the Entire Booster Phase(From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months))
Percentage of Participants With Related AESIs During the Entire Booster Phase(From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months))
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Booster Phase(SAEs and AESIs: From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months); AEs: From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month))
GMTs for IgG Against Each OspA Serotype During the Main Study Phase(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 365 (Month 12) and Day 545 (Month 18))
SCRs for Each OspA Serotype Specific IgG During the Main Study Phase(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
Percentage of Participants Adverse Event of Special Interest (AESIs) During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
Percentage of Participants With SAEs, AESIs, Solicited and Unsolicited AEs Stratified by Age Group During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
Percentage of Participants With Related Unsolicited AEs During the Booster Phase up to Month 19(From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month))
GMTs for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 18 - 49 Years(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
SCR for IgG Against Each OspA Serotype Stratified by Age Group During Main Study Phase: Group 50 - 65 Years(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12) and Day 545 (Month 18))
Percentage of Participants With Related SAEs During the Main Study Phase(From Day 1 of vaccination up to Day 545 (Month 18))
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
Percentage of Participants With Unsolicited AEs During the Booster Phase up to Month 19(From Day of vaccination in booster phase (Month 18) up to Month 19 (Approximately for 1 Month))
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Each and After Any Vaccination During the Main Study Phase(Up to 7 days after Vaccination 1, 2 and 3; Up to 7 days after any vaccination)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6): Booster Per-protocol (PP) Population(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
GMFR as Compared to Day 208 for IgG Against Each OspA Serotype (ST1 to ST6): Booster PP Population(Day 208 (from where comparison was done), Month 19, Month 24 and Month 30)
Percentage of Participants With Solicited Local and Solicited Systemic AEs Within 7 Days After Booster Vaccination(Within 7 days after booster vaccination)
GMTs for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 50 - 65 Years(At Day 1 (Month 0), Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
SCR for IgG Against Each OspA Serotype (ST1 to ST6) Stratified by Age Group in Booster PP Population: Group 18 - 49 Years(Day 29 (Month 1), Day 57 (Month 2), Day 85 (Month 3), Day 180 (Month 6), Day 208 (Month 7), Day 365 (Month 12), Day 545 (Month 18), Month 19, Month 24, and Month 30)
Percentage of Participants With SAEs During the Entire Booster Phase(From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months))
Percentage of Participants With Adverse Event of Special Interest (AESIs) During the Entire Booster Phase(From Day of vaccination in booster phase (Month 18) up to Month 30 (Approximately maximum up to 12 Months))

研究者

发起方

Pfizer

申办方类型

Industry

责任方

Sponsor

研究点 (5)

Loading locations...

相似试验

已完成

3 期

A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder SyndromeOveractive Bladder Syndrome

NCT00220363Pfizer

已完成

3 期

Phase III Confirmatory Study in Erythropoietic ProtoporphyriaErythropoietic Protoporphyria

NCT01605136Clinuvel Pharmaceuticals Limited93

已完成

3 期

Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer TherapyCancer Therapy-Related DiarrheaChemotherapy-related DiarrheaProphylaxis of DiarrheaSymptomatic Relief of DiarrheaAdult Solid TumorTargeted Therapy-related Diarrhea

NCT04538625Napo Pharmaceuticals, Inc.287

进行中（未招募）

2 期

NCT04739800National Cancer Institute (NCI)120

已完成

2 期

Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive BladderUrinary Bladder, Overactive

NCT00479505Pfizer275